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New methods for creating theranostic systems with simultaneous encapsulation of 
therapeutic, diagnostic and targeting agents are much sought after. This work 
reports for the first time the use of coaxial electrospinning to prepare such systems 
in the form of core-shell fibers. Eudragit S100 was used to form the shell of the fibers, 
while the core comprised polyethylene oxide loaded with the magnetic resonance 
contrast agent Gd(DTPA) (Gd(III) diethylenetriaminepentaacetate hydrate) and 
indomethacin as a model therapeutic agent. The fibers had linear cylindrical 
morphologies with clear core-shell structures, as demonstrated by electron 
microscopy. X-ray diffraction and differential scanning calorimetry proved that both 
indomethacin and Gd(DTPA) were present in the fibers in the amorphous physical 
form. This is thought to be a result of intermolecular interactions between the 
different components, the presence of which was suggested by IR spectroscopy. In 
vitro dissolution tests indicated that the fibers could provide targeted release of the 
active ingredients through a combined mechanism of erosion and diffusion. The 
proton relaxivities for Gd(DTPA) released from the fibers into tris buffer increased 
(r1=5.03-10.13 s
-1 mM-1;  r2=8.28-14.96 s
-1 mM-1) compared with fresh Gd(DTPA) 
(r1=4.37 s
-1mM-1 and r2=4.85 s
-1mM-1), proving that electrospinning has not 
diminished the contrast properties of the complex. The new systems reported herein 
thus offer a new platform for delivering therapeutic and imaging agents 
simultaneously to the colon.  
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In current medicine, disease (particularly tumor) detection and therapy are largely 
performed separately. However, it can be much more effective to combine 
molecular diagnosis and therapy, performing both simultaneously in an approach 
known as theranostics.1 This has shown great potential in molecular diagnosis, 
molecular therapy, imaging-guided drug delivery and treatment monitoring. It can 
help to ensure effective drug delivery through the noninvasive assessment of 
biodistribution, the optimization of strategies for triggered drug release, and 
real-time monitoring of therapeutic responses.1 It can not only increase drug efficacy 
and safety, but can also eliminate the unnecessary treatment of patients for whom a 
particular therapy is not appropriate, resulting in significant cost savings for 
healthcare systems.2  
 
An effective way to develop a theranostic system is to incorporate both the 
therapeutic and the diagnostic agents simultaneously into a single product.3 These 
systems to date have mainly taken the form of nanoparticles for applications in 
treating cancer patients.4 A variety of materials, such as inorganic5 and polymeric 
nanoparticles,6 have been prepared carrying both a diagnostic agent and a drug to 
achieve magnetic resonance imaging (MRI) and therapeutic drug delivery 
simultaneously. However, time-consuming processes comprising multiple steps are 
typically required for the preparation of such multifunctional carriers, which are also 
very difficult to produce on a large scale.3,7-10 New methods for creating nanoscale 
theranostic systems are thus much sought after.    
 
Electrospinning is a popular process widely used for generating polymer-based fibers. 
A polymer/active ingredient solution is first prepared, and loaded into a syringe 
fitted with a metal needle. The solution is ejected from the syringe towards a metal 
collector at a controlled rate, and a high voltage applied between the two. This 
results in rapid evaporation of the solvent, and the formation of one-dimensional 
polymer fibers. Electrospinning is simple and cheap to implement, and a wide variety 
of functional ingredients can be easily incorporated into the polymer matrix.8,11,12 
Electrospun fibers have been found to be good candidates for a wide variety of 
biomedical applications such as cardiovascular stents,13 wound healing,14 and the 
controlled release of active ingredients.15-17 Electrospun drug-loaded fibers have 
been broadly explored for targeted release, for improving the dissolution rate of 
poorly water-soluble drugs, and for encapsulating multiple functional 
components.18-20 The simplest process involves a single needle, and produces 
monolithic fibers. The more advanced coaxial process (this uses two needles and 
solutions, one nested inside the other) can generate core-shell fibers, with a number 
of concomitant advantages. The incorporation of a drug only in the core of the fibers 
can protect it from heat or light, or preclude release in an inappropriate pH medium. 
If the fibers are appropriately designed, core-shell drug-loaded fibers can 
additionally eliminate the initial burst release commonly seen with monolithic fibers, 
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resulting in zero-order release materials or multiple-phase controlled release.21,22 
The simultaneous release of multiple drugs is also possible,23,24 and a wider range of 
polymers can be processed with the coaxial approach than with single-fluid 
spinning.25  
 
Given that multiple drugs can be incorporated into coaxial electrospun fibers and 
released into particular parts of the body, here we aimed to fabricate a series of 
novel theranostic systems using this process. The literature is mainly focused on 
theranostics for cancer treatment, but this work is focused on systems for the 
diagnosis and treatment of inflammatory bowel disease (IBD). Anti-inflammatory 
drugs are often the first step in the treatment of IBD: hence, indomethacin, a 
non-steroidal anti-inflammatory drug commonly used to reduce fever, pain and 
inflammation, was used as a model therapeutic agent.26 Core/shell fibers were 
prepared with Eudragit S100, a pH-sensitive polymer commonly used as a coating to 
avoid drug release in the stomach, as the shell polymer.27 The biocompatible 
polyethylene oxide (PEO), which has a particular ability to adhere strongly to the 
colonic mucosa,28 was selected as the core polymer. Indomethacin and the 
widely-used MRI contrast agent Gd(DTPA),3 were both incorporated into the core of 
the fibers. 
 
This work builds on our previous research in which we successfully produced 
core-shell fibers loaded with Gd(DTPA) by coaxial electrospinning.29 Gd(DTPA) was 
found to retain its ability to act as contrast agent after electrospinning. It was also 
demonstrated that functional ingredients embedded in the core of the fibers can be 
effectively transferred to the colonic mucosa, permitting the latter to be imaged. 
  
The experimental strategy for the production of electrospun theranostics is 
illustrated schematically in Figure 1. The Eudragit shell is insoluble in acidic pHs, and 
thus the fibers are not expected to free any of their indomethacin or Gd(DTPA) 
loading in the stomach. When the fibers reach the lower (and higher pH) parts of the 
intestine the shell will dissolve, exposing the PEO core to the gastric fluids. The PEO 
will swell and mucoadhere to the walls of the intestine. As it does so, the Gd(DTPA) 
and indomethacin will be freed and will permeate the colon wall for simultaneous 
imaging and treatment of IBD. A family of fibers was prepared with different 
molecular weight PEOs and loadings of active ingredients, fully characterized, and its 














Figure 1. A schematic diagram illustrating the coaxial electrospinning process and the planned 
application of the resultant fibers.  
 
Experimental section 
Materials. Gadolinium(III) diethylenetriaminepentaacetate dihydrogen hydrate 
Gd(DTPA) and arsenazo III were purchased from Sigma-Aldrich UK. Eudragit S100 
(Mw=125 kDa) was obtained from Rohm GmbH. Polyethylene oxide samples of 
different molecular weights were provided by Acros Organics UK (Mw=600 kDa; PEO 
0.6M) or Colorcon Ltd (Mw=1000 kDa; PEO 1M). Gadolinium chloride hexahydrate, 
diethylenetriaminepentaacetic acid, and lanthanum oxide were supplied by Alfa 
Aesar UK. Indomethacin was provided by Molekula Ltd. 
 
Anhydrous ethanol and acetone were analytical grade and procured from Fisher 
Scientific. Triton X100 and dimethylacetamide (DMAc) were supplied by 
Sigma-Aldrich. All water was deionised prior to use. 
 
Preparation of working solutions. The shell solution consisted of 13.5% w/v of 
Eudragit S100 (ES100) in a mixture of ethanol and DMAc (8:2 v/v). A number of core 
solutions with varied contents of Gd(DTPA) and indomethacin with PEO 0.6M or PEO 
1M were prepared. The solvent for the core solution was composed of water/ethanol 
(3:7 v/v) with additives (acetone, 1% v/v; Triton X100, 0.1% v/v) included to ensure 

























Composition of the core 
/ % w/w 
F1 600 3 2 : 10 2 : 10 
14.3 % Gd(DTPA); 
14.3 % indomethacin; 
71.4 % PEO 
F2 1000 2 1 : 10 1 : 10 
8.3 % Gd(DTPA); 
8.3 % indomethacin; 
83.4 % PEO 
F3 1000 2 2 : 10 2 : 10 
14.3 % Gd(DTPA); 
14.3 % indomethacin; 
71.4 % PEO 
F4 1000 2 3 : 10 3 : 10 
18.8 % Gd(DTPA); 
18.8 % indomethacin; 
62.5 % PEO 
 
Coaxial electrospinning. A homemade concentric spinneret was used for coaxial 
spinning. This was prepared by inserting a small stainless steel needle (27G; outer 
and inner diameters of 0.42 and 0.21 mm, respectively) into a larger needle (18G; 
outer and inner diameters of 1.25 and 0.84 mm). A HCP 35-35000 power supply (FuG 
Elektronik GmbH) was employed to provide high voltages. The spinning solutions 
were loaded into two 10 mL syringes and these were connected to the spinneret. 
Great care was taken to avoid air bubbles in the solution. An alligator clip (the 
positive electrode) was then attached to the concentric needle. The grounded 
electrode was connected to a flat collector wrapped in aluminum foil. 
Electrospinning was accomplished under ambient conditions (22 ± 3 °C and relative 
humidity 30 ± 5 %). Two syringe pumps (KDS 100, Cole-Parmer) were used to drive 
the working solutions. After a series of preliminary optimization experiments the 
applied voltage was set to 10 kV, with a spinneret-to-collector distance of 20 cm. The 
shell and core fluid flow rates were fixed at 1.5 and 0.3 mL/h, respectively.  
 
Synthesis of lanthanum(III) diethylenetriaminepentaacetate (La(DTPA)). La(DTPA) 
was prepared following a literature method for Gd(DTPA).30 A suspension of 
diethylenetriaminepentaacetic acid (0.7868 g, 2 mmol) and lanthanum oxide (0.3261 
g, 1 mmol) in 100 mL deionised water was refluxed with stirring for 2 h, after which 
the solution was clear. The solvent was evaporated by rotary evaporation, after 
which the solid product was recovered and washed with methanol and dried under 
vacuum. (Found: C, 28.59; H, 4.56; N, 6.64%. Calc’d. for 
LaC14H20O10N3·2.2H2O·CH3OH·0.088La2O3: C, 28.62; H, 4.55; N, 6.67%). 
 
Characterization. Scanning Electron Microscopy. The morphology of the fibers was 
examined using a scanning electron microscope (SEM; FEI Quanta 200 FEG ESEM 
instrument). Prior to examination, samples were gold sputter-coated under a 
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nitrogen atmosphere to render them electrically conductive. The average fiber 
diameter was determined by measuring their sizes in FESEM images at more than 
100 different places, using the Image J software (National Institutes of Health). 
 
Transmission electron microscopy. Transmission electron microscopy (TEM) images of 
the core-shell fibers were recorded on a Philips CM 120 Bio-Twin instrument. 
Samples for TEM were prepared by fixing a lacey carbon-coated copper grid directly 
onto the collector and electrospinning onto it for several minutes. 
 
Differential scanning calorimetry. Differential scanning calorimetry (DSC) was carried 
out using a Q2000 instrument (TA Instruments). Sealed samples were heated at 
10 °C/min from ambient temperature to 180 °C under a nitrogen gas flow of 50 
mL/min.  
 
X-ray diffraction. X-ray diffraction (XRD) was conducted using a Rigaku MiniFlex 600 
instrument with Cu Kα radiation over the 2θ range 10° to 35°, at 40 kV and 15 mA.  
 
Fourier transform infrared spectroscopy. Fourier transform infrared (FTIR) 
spectroscopy was carried out on a Spectrum 100 spectrometer (PerkinElmer). 
Spectra were recorded over the range of 700 cm–1 to 1800 cm–1 at a resolution of 2 
cm−1. 
 
Proton NMR Spectroscopy. NMR spectra were recorded on a Bruker Avance 400 
instrument (1H frequency: 400.1 MHz). La(DTPA) (10 mg), indomethacin (10 mg), PEO 
(20 mg), physical mixtures of polymer and La(DTPA) (10 – 20 mg), and PEO fibers (20  
mg) loaded with indomethacin only were all dissolved in 1 mL of D2O or MeOD, and 
transferred into a 5 mm-diameter NMR tube for measurement. 
 
Gd(III) leaching studies. To monitor leaching of Gd(III) ions from the core-shell fibers, 
approximately 5 mg of each fiber mat was incubated in 4 mL of 0.05 mM arsenazo-III 
solution (pH 7.4) to permit free Gd(III) ions to form a complex with the arsenazo 
ligand. The resultant suspension was filtered through a 0.45 μm filter. The filtrate was 
then analysed at 654 nm on a Jenway 7315 uv/vis spectrophotometer. Water and a 
0.076 mM GdCl3 solution were used as negative and positive controls respectively. 
 
Microwave plasma-atomic emission spectroscopy. The Gd(III) contents of the fibers 
were determined by microwave plasma-atomic emission spectroscopy (MP-AES; 
4100 instrument, Agilent Technologies). Linear calibration curves were constructed 
over the range 1.56-50 ppm. Three samples (ca. 10 mg) for each fiber were digested 
in 5 cm3 tris buffer before analysis. The Gd(II) lines at 376.84 nm and 409.86 nm were 
used for quantification, and each sample was measured three times. 
 
In vitro dissolution test. In vitro dissolution tests were conducted using a mini paddle 
dissolution apparatus (PTWS model, Pharma Test). Approximately 100 mg of 
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Gd(DTPA) / indomethacin loaded fibers were placed in 150 mL of 0.1 N HCl and were 
transferred to 150 mL of phosphate buffered saline (PBS; pH 7.4) 2 h later. The 
medium was kept at 37 ± 1 °C and was stirred at a constant speed of 50 rpm under 
sink conditions. 5 mL aliquots were withdrawn from the dissolution medium at 
predetermined time points, and replaced by 5 mL of fresh pre-heated medium. The 
indomethacin concentration in the aliquots was quantified at λmax=266 nm using a 
Jenway 7315 UV/vis spectrophotometer. Gd(III) concentrations were analysed by 
microwave plasma-atomic emission spectroscopy as detailed above. Each experiment 
was repeated three times, and results are reported as mean ± S.D.  
 
Proton NMR relaxivity measurements. The longitudinal (T1; 20 data points) and 
transverse relaxation times (T2; 400 data points) of water protons were recorded on a 
Minispec mq20 relaxometer (20 MHz, 0.47 T, Bruker Corporation) at 37 °C, using 
inversion recovery and CPMG pulse sequences, respectively. Solutions of the fibers in 
tris buffer with 0.5, 0.75 and 1 mM Gd(III) concentrations were loaded in 10 
mm-diameter NMR tubes and warmed to 37 °C in a water bath prior to 
measurement. Each sample was measured three times. Relaxivities were calculated 
on the basis of a two-point calibration (fibers and no fibers) using the equation 1/T1/2 
= r1/2 × [Gd]. 
 
Results and discussion 














Figure 2. SEM images of the core-shell fibers and their diameter distributions: (a) F1, (b) F2, (c) F3 
and (d) F4. 
 
Figure 2 shows the SEM images of the four fiber samples. All have cylindrical shapes, 
linear morphologies, smooth surfaces and relatively uniform diameter distributions. 
The average diameter of the core-shell fibers with PEO 1M as the core increased 
slightly from 0.93 ± 0.23 μm (F2) to 1.11 ± 0.31 μm (F4) as the total content of 
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indomethacin and Gd(DTPA) increased from 16.6 % w/w in F2 (8.3 % indomethacin 
and 8.3 % Gd(DTPA)) to 37.6 % (18.8 % indomethacin and 18.8 % Gd(DTPA)) for F4, 
as can be seen in Table 2 and Figure 2b to 2d. Similar results have previously been 
reported for monolithic drug-loaded ES100 fibers fabricated using a single fluid 
electrospinning process.31 The average diameter of F1 is 1.05 ± 0.20 μm (Table 2 and 
Figure 2a). No particles can be seen on the surfaces of any of the fibers, suggesting 
no separation of indomethacin or Gd(DTPA) during the electrospinning process.     
 








F1 linear 1.05 ± 0.20 160 566 
F2 linear 0.93 ± 0.23 218 277 
F3 linear 1.01 ± 0.23 198 615 













Figure 3. TEM images of the fibers: (a) F1, (b) F2, (c) F3 and (d) F4. 
  
TEM images of the four fibers are given in Figure 3. The core-shell morphology is 
evident in all cases although no clear-cut boundaries can be discerned between their 
outer shells and inner cores. The estimated values of the core and shell thicknesses 
of these fibers are shown in Figure 3 and also summarized in Table 2. In some images, 
there appear to be several nanoparticles in the cores of the fibers (Figure 3a and c), 














Physical form of the components and their compatibility  
 
Figure 4. (a) DSC thermograms of the raw materials, a physical mixture, and fibers F1, F2, F3 and 
F4; (b) Enlargements exhibiting the glass transitions of Eudragit S100, a physical mixture, and 
fibers F1, F2, F3 and F4.    
 
DSC thermograms are presented in Figure 4. Indomethacin is a crystalline material, as 
demonstrated by the presence of a sharp endothermic melting peak at 161 °C in its 
DSC trace.26 PEO 1M shows an onset melting point at 62 °C, while ES100 displays no 
melting events, but a glass transition at around 111 °C. This is because the former is a 
semi-crystalline polymer while the latter is amorphous. The Gd(DTPA) thermogram 
does not exhibit any melting events, again because it is amorphous. For the physical 
mixture, there are three phase transitions. The two sharp peaks at 64 °C and 160 °C 
correspond to the onset melting points of PEO and indomethacin respectively, while 
the glass transition temperature at 113 °C is attributable to the presence of ES100. 
No fusion events are detectable in the DSC thermograms of any of the fibers, 
suggesting that both indomethacin and Gd(DTPA) are present in the fibers in an 
amorphous state. The Tg of Eudragit can be seen to be reduced from that of the raw 





Figure 5. XRD patterns of the raw materials, a physical mixture, and fibers F1, F2, F3 and F4.   
 
XRD patterns are depicted in Figure 5. The pattern of raw ES100 shows only a broad 
halo, consistent with the DSC data and proving that the material is amorphous. The 
PEO 1M powder exhibits two broad reflections at around 2θ = 19° and 2θ = 23° since 
PEO is semi-crystalline. No Bragg reflections are observed in the X-ray diffraction 
pattern of Gd(DTPA), while for indomethacin multiple reflections are present. These 
results concur with the DSC, demonstrating Gd(DTPA) to be amorphous and 
indomethacin crystalline. The XRD pattern of a physical mixture shows characteristic 
reflections corresponding to raw indomethacin and PEO. In contrast, the patterns for 
the fibers are devoid of any diffraction features, showing the components all to be 







Figure 6. (a) FTIR spectra of the raw materials, a physical mixture, and fibers F1, F2, F3 and F4; (b) 
Chemical structures of the raw materials.  
 
To evaluate the component compatibility, FTIR spectroscopy was used to analyze the 
samples (see Figure 6a). In the spectrum of indomethacin, the characteristic peaks at 
1713 cm-1 and 1690 cm-1 are associated with aliphatic and benzoyl carbonyl vibration 
stretching respectively. Other absorbance peaks are visible at 1478 (C=C of aromatic 
rings), 1308 (C-O of acidic group), 1270-1200 (=C-O of ether group) and 1066 cm-1 
(C-Cl).32 ES100 shows a characteristic peak at 1726 cm-1 corresponding to carbonyl 
stretching, with other absorbances present at 1263 and 1157 cm-1 and corresponding 
to C-O-C stretching vibrations. The characteristic absorption peaks at 1585 cm-1 and 
1408 cm-1 in the spectrum of Gd(DTPA) are associated with asymmetric and 
symmetric COO stretching vibrations. 
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For the physical mixture, the characteristic peaks at 1713 and 1290 cm-1 for 
indomethacin, 1585 cm-1 for Gd(DTPA) and 1151 cm-1 for ES100 can be observed, but 
the peaks for PEO are masked by the other three materials. The peak positions of the 
physical mixture are unchanged from the raw materials, indicating that few 
interactions occur between the components when they are simply mixed. In 
comparison with the physical mixture, the characteristic peaks of Gd(DTPA) (1585 
cm-1) and indomethacin (1690, 1713 cm-1) cannot be resolved in the spectra of the 
fibers. Almost all the peaks in the fingerprint region of indomethacin have shifted, 
decreased in intensity, or disappeared in the fibers’ spectra. These phenomena 
suggest that secondary interactions such as hydrogen bonding and hydrophobic 
interactions occur between the polymer matrix and the loaded active ingredients. By 





The leaching of free Gd(III) ions from the fibers could lead to toxicity, because Gd(III) 
has high affinity for Ca(II) binding sites. This causes interference with Ca(II) channels 
and causes Gd(III) to be deposited in the liver and bone.33,34 To investigate the 
possibility that free Gd(III) may leach from the fibers, the composite materials were 
incubated with arsenazo III (0.05 mM) at 37 °C in a pH 7.4 tris buffer. The absorbance 
band of the Gd(III)-arsenazo III complex at 654 nm was then investigated. Tris buffer 
and GdCl3 incubated with arsenazo III were used as negative and positive controls. 













Figure 7. UV absorption spectra of samples F1, F2, F3 and F4 (Gd(III) concentrations: 0.025, 0.030, 
0.034, and 0.038 mM respectively) incubated with arsenazo III. An aqueous 0.076 mM GdCl3 
solution acted as the positive control. 
 
The positive and negative controls have absorbance values of 0.991 and 0.339 
respectively at 654 nm, while the absorbance of the dissolved fibers is very close to 
that of the negative control. For the low loading fibers F2, no Gd(III) could be 
detected in solution with an observed absorbance value of 0.317. As the content of 
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Gd(DTPA) increases (F3 and F4), the intensity of absorbance at 654 nm increases 
slightly from 0.385 to 0.394, indicating that after complete dissolution of the fibers 
less than 6 % of the Gd incorporated was leached as the uncomplexed Gd(III) ion. 
 
Overall, these results show that there is no significant leaching of free Gd(III) ions 
from the fibers – if free ions were present in solution they would complex with the 
arsenazo-III leading to increased absorbance at 654 nm, while Gd(III) complexed in 
Gd(DTPA) cannot bind with the arsenazo ligand and hence there is no additional 
absorbance at this wavelength. 
 
1H Nuclear magnetic resonance 
The chemical integrity of Gd(DTPA) can be proved by 1H NMR using the analogous 
La(DTPA) species as a model. 1H NMR spectra are provided in Figure S1. Comparing 
the NMR spectrum of the dissolved fibers with that of raw indomethacin shows that 
the chemical structure of indomethacin is intact both after being mixed physically 
with PEO or after incorporation into PEO monolithic fibers, consistent with reported 
findings from the literature.35 In addition, La(DTPA) also does not seem to be 
degraded after electrospinning. It still displays multiplets in the range of 1.0 – 2.0 
ppm because of ligand coordination to the La(III) ion. Therefore, it can be confirmed 
that the complex structure remains intact after electrospinning, and thus the 
Gd(DTPA) fibers are expected to be potent as contrast agents.  
 
In vitro drug release  
To mimic the conditions of the human gastrointestinal tract, drug release from the 
core-shell fibers was first carried out in an acidic solution (0.1 N HCl, simulated 
gastric fluid) for 2 hours and subsequently in a PBS buffer (pH 7.4, simulated 
intestinal fluid). The amount of indomethacin released from the fibers was measured 
at 266 nm by UV spectroscopy. A pre-determined calibration curve was used to 
determine drug concentration:  
A = 0.0491C + 0.0044 (R=0.9999) 
Where C is the indomethacin concentration (mg/L) and A is the absorbance value at 
266 nm (linear range: 0.156-20 mg/L). 
 




Figure 8. In vitro drug release profiles. 
 
In 0.1 N HCl, no more than 10 % of indomethacin was released from the composite 
fibers after 2 h. This is because ES100 is insoluble under these pH conditions. After 
being transferred to a PBS buffer (pH 7.4), sustained release of indomethacin from 
the fibers was observed until 100 % release was reached. The mechanism of 
indomethacin release was analyzed using the Peppas equation36: 
Q = ktn    
where Q is the drug release percentage, t is the release time, k is a rate constant, 
and n is an exponent that indicates the drug release mechanism. Regressed 
equations were determined for the release data at pH 7.4 (t = the time at pH 7.4) 
over the period t = 1-8 h for F1 and t = 1-6 h for F2 to F4, and found to be Q1 = 
24.15t1
0.587 (R1
2 = 0.996); Q2 = 37.81t2
0.602 (R2
2 = 0.962); Q3 = 47.37t3
0.428 (R3
2 = 0.954) 
and Q4 = 53.37t4
0.311 (R4
2 = 0.941), respectively. The release exponent values are 
0.587, 0.602, 0.428 and 0.311. The release exponents for the fibers F1 and F2 are 
larger than 0.45 but smaller than 1.0, suggesting that the drug was freed into 
solution through a combined mechanism of polymer erosion and drug diffusion.37 
However, fibers F3 and F4 had a release exponent smaller than 0.45, suggesting a 
typical Fickian diffusion mechanism is operational here.  
 
The amount of Gd(DTPA) released from the fibers could not easily be quantified as a 
function of time because the concentrations released were very close to the 
detection limit of the MP-AES instrument. The cumulative amount of complex 
released from 150 mg of F1 – F4 was quantified, however, and found to be in the 
range of 2.78 to 7.12 μmol (see Table S1). Clinically used preparations of Magnevist, 
use typically 7.5 to 10 μmol of Gd(DTPA) for colorectal lesion detection.38 Thus, 160 – 






The longitudinal and transverse relaxivities of Gd(DTPA) and the fibers after 
dissolution in tris buffer are listed in Table 3. The relaxivities were measured by 
recording the longitudinal and transverse relaxation rates and the normalized 
concentration of contrast agent or metal ion (M).  
 
Table 3. Proton relaxivities recorded after dissolution in a tris buffer. Results are reported as 
mean ± SD, n = 3. 





1.00 226.20 ± 1.91 209.46 ± 2.48 4.42 ± 0.04 4.77 ± 0.06 
Gd(DTPA) in tris 
buffer 
1.00 228.65 ± 0.49 206.06 ± 1.78 4.37 ± 0.01  4.85 ± 0.04 
Gd(DTPA)+ 
PEOa 
1.00 225.85 ± 0.07 202.83 ± 2.01 4.43 ± 0.00 4.93 ± 0.05 
Gd(DTPA)+PEO
+Eudragita 
1.00 143.40 ± 0.95 121.96 ± 0.60 6.97 ± 0.05 8.20 ± 0.04 
F1 1.24 160.13 ± 0.76 97.37 ± 1.12 5.03 ± 0.02 8.28 ± 0.10 
F2 0.48 268.50 ± 2.12 139.30 ± 2.40 7.76 ± 0.06 14.96 ± 0.26 
F3 0.79 125.00 ± 3.00 86.19 ± 3.12 10.13 ± 0.24 14.69 ± 0.53 
F4 0.99 140.80 ± 1.15 87.25 ± 1.83 7.21 ± 0.06 11.64 ± 0.24 
a physical mixtures. 
 
Tris buffer has little effect on the relaxivity of Gd(DTPA), and the r1 and r2 values are 
very close to those observed in water. The slight increase in relaxivities observed with 
a physical mixture of ES100, PEO and Gd(DTPA) is likely to be a result of the tris 
bridging between ES100/PEO and Gd(DTPA) through hydrogen bonding and 
electrostatic interactions, resulting in slower rotational motion.39 Consequently, all 
the composite fibers display increased longitudinal relaxivities from 5.03 to 10.13 
s-1mM-1 and transverse relaxivities from 8.28 to 14.96 s-1mM-1. The ratio of r2/r1 for 
the coaxial materials dissolved in tris buffer ranges from 1.45 - 1.93 [cf. 1.11 for 
Gd(DTPA)]. Contrast agents with small r2/r1 values are found to be efficient as T1 MRI 
contrast agents.40 Similar values of r2/r1 (1.56 - 1.85) were reported for Gd(III) ions 
incorporated into mesoporous silica nanoparticles.41 These data demonstrate that 
the formulation prepared in this work should be potent as MRI contrast agents. 
   
To investigate the possible effect of indomethacin on the relaxation properties, it is 
helpful to consider these systems in comparison with a control set of Eudragit 
S100/PEO fibers loaded with only Gd(DTPA) prepared in a previous study.29 In 
comparison with the relaxivities of fibers loaded with Gd(DTPA) only (Tables S2 and 
S3), those of Gd(DTPA)/indomethacin fibers were found to be somewhat lower (e.g. 
F3 has r1=10.13 s
-1mM-1 and r2=14.69 s
-1mM-1, while the indomethacin-free analogue 
F3’ has r1=12.29 s
-1mM-1 and r2=18.68 s
-1mM-1). This could possibly be due to changes 
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in the accessibility of water molecules to the Gd(III) centre when indomethacin is 
present.3,42 However, in general the presence of indomethacin has little influence on 
the relaxivities. The co-encapsulation of Gd(DTPA) and indomethacin in electrospun 




Core-shell fibers comprising a shell of Eudragit S100 and polyethylene oxide cores 
loaded with both Gd(DTPA) and indomethacin were successfully prepared using 
coaxial electrospinning. The characterizing data showed the fibers to be uniform and 
cylindrical in morphology, with distinct shell and core compartments and containing 
an amorphous dispersion of active ingredients. The indomethacin release profiles 
into gastrointestinal-like media showed little release at pH 1 and sustained release 
over 12 – 29 h at pH 7.4. The proton relaxivities for Gd(DTPA) released from the 
fibers in tris buffer increased (r1=5.03-10.13 s
-1mM-1; r2=8.28-14.96 s
-1mM-1) 
compared with the pure Gd(DTPA) complex (r1=4.37 s
-1mM-1 and r2=4.85 s
-1mM-1). 




Details of the Gd(DTPA) loadings of the fibers, r1 and r2 values of fibers containing 
Gd(DTPA) without indomethacin, NMR data for La(DTPA) systems. This material is 
available free of charge via the Internet at http://pubs.acs.org. 
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